Felix Rohdich
Felix Rohdich has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Amy Hin Yan Tong
Donnelly Centre, University of Toronto, Toronto, Canada
63 shared publications - Andree Blaukat
Translational Innovation Platform Oncology and Immuno-Oncology, The Healthcare Business of Merck KGaA, Darmstadt, Germany
63 shared publications - Beatrix Blume
Discovery Technologies, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany
63 shared publications - Birgitta Leuthner
The healthcare business of Merck KGaA, Darmstadt, Germany
63 shared publications - Diane Hahn
Research Unit Oncology, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany
63 shared publications - Dirk Wienke
The healthcare business of Merck KGaA, Darmstadt, Germany
63 shared publications
Latest Publications
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7-2 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Top CRISPR hits that score as suppressors or sensitizers
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7-2 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Top CRISPR hits that score as suppressors or sensitizers
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7-1 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Bayes Factor (BF) scores of MetAP1 and MetAP2 in the screens
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7-1 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Bayes Factor (BF) scores of MetAP1 and MetAP2 in the screens
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Data from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
N-terminal processing by methionine aminopeptidases (MetAP) is a crucial step in the maturation of proteins during protein biosynthesis. Small-molecule inhibitors of MetAP2 have antiangiogenic and antitumoral activity. Herein, we characterize the structurally novel MetAP2 inhibitor M8891. M8891 is a potent, selective, reversible small-molecule inhibitor blocking the growth of human endothelial cells and differentially inhibiting cancer cell growth. A CRISPR genome-wide screen identified the tumor suppressor p53 and MetAP1/MetAP2 as determinants of resistance and sensitivity to pharmacologic MetAP2 inhibition. A newly identified substrate of MetAP2, translation elongation factor 1-alpha-1 (EF1a-1), served as a pharmacodynamic biomarker to follow target inhibition in cell and mouse studies. Robust angiogenesis and tumor growth inhibition was observed with M8891 monotherapy. In combination with VEGF receptor inhibitors, tumor stasis and regression occurred in patient-derived xenograft renal cell carcinoma models, particularly those that were p53 wild-type, had Von Hippel-Landau gene (VHL) loss-of-function mutations, and a mid/high MetAP1/2 expression score.
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
N-terminal processing by methionine aminopeptidases (MetAP) is a crucial step in the maturation of proteins during protein biosynthesis. Small-molecule inhibitors of MetAP2 have antiangiogenic and antitumoral activity. Herein, we characterize the structurally novel MetAP2 inhibitor M8891. M8891 is a potent, selective, reversible small-molecule inhibitor blocking the growth of human endothelial cells and differentially inhibiting cancer cell growth. A CRISPR genome-wide screen identified the tumor suppressor p53 and MetAP1/MetAP2 as determinants of resistance and sensitivity to pharmacologic MetAP2 inhibition. A newly identified substrate of MetAP2, translation elongation factor 1-alpha-1 (EF1a-1), served as a pharmacodynamic biomarker to follow target inhibition in cell and mouse studies. Robust angiogenesis and tumor growth inhibition was observed with M8891 monotherapy. In combination with VEGF receptor inhibitors, tumor stasis and regression occurred in patient-derived xenograft renal cell carcinoma models, particularly those that were p53 wild-type, had Von Hippel-Landau gene (VHL) loss-of-function mutations, and a mid/high MetAP1/2 expression score.
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9-1 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Antitumor activity of M8891 monotherapy evaluated in vivo in 10 PDX models (NSCLC, head and neck, colon, osteosarcoma, and gastric cancer) selected from the PDX in vitro evaluation (IC50 <1E−06 M)
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9-1 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Antitumor activity of M8891 monotherapy evaluated in vivo in 10 PDX models (NSCLC, head and neck, colon, osteosarcoma, and gastric cancer) selected from the PDX in vitro evaluation (IC50 <1E−06 M)
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11-5 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Body weight curves for renal cancer PDX model RXF-2717-bearing mice treated with vehicle, M8891 (100 mg/kg, daily, per os), axitinib (4 mg/kg, twice daily, per os), or the combination are shown
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11-5 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Body weight curves for renal cancer PDX model RXF-2717-bearing mice treated with vehicle, M8891 (100 mg/kg, daily, per os), axitinib (4 mg/kg, twice daily, per os), or the combination are shown
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9-1 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Antitumor activity of M8891 monotherapy evaluated in vivo in 10 PDX models (NSCLC, head and neck, colon, osteosarcoma, and gastric cancer) selected from the PDX in vitro evaluation (IC50 <1E−06 M)
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9-1 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Antitumor activity of M8891 monotherapy evaluated in vivo in 10 PDX models (NSCLC, head and neck, colon, osteosarcoma, and gastric cancer) selected from the PDX in vitro evaluation (IC50 <1E−06 M)
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-2 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Increasing concentrations of M8891 (3E−10M to 1E−05M) were tested in a murine MetAP2 enzyme assay
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-2 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Increasing concentrations of M8891 (3E−10M to 1E−05M) were tested in a murine MetAP2 enzyme assay
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11-2 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Body weight curves of RCC PDX model RXF-SMTCA75-bearing mice treated with vehicle, M8891 (100 mg/kg, daily, per os), sunitinib (40 mg/kg, daily, per os), or the combination are shown
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11-2 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Body weight curves of RCC PDX model RXF-SMTCA75-bearing mice treated with vehicle, M8891 (100 mg/kg, daily, per os), sunitinib (40 mg/kg, daily, per os), or the combination are shown
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary methods S6 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Generation of rabbit monoclonal antibody against unprocessed human EF1a
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary methods S6 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Generation of rabbit monoclonal antibody against unprocessed human EF1a
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-2 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Increasing concentrations of M8891 (3E−10M to 1E−05M) were tested in a murine MetAP2 enzyme assay
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-2 from Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Increasing concentrations of M8891 (3E−10M to 1E−05M) were tested in a murine MetAP2 enzyme assay